Phase II study of DFP-14323 with low dose EGFR-TKI for EGFR mutation positive NSCLC.
Phase of Trial: Phase II
Latest Information Update: 12 Jul 2019
Price : $35 *
At a glance
- Drugs Afatinib (Primary) ; DFP-14323 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Delta-Fly Pharma
- 10 Jul 2019 Planned End Date changed from 31 Oct 2019 to 30 Apr 2022.
- 26 Jun 2018 New trial record